PTCB Guide to Antidiabetic Drugs
Also called oral antidiabetic medications and injectable non-insulin agents for type 2 diabetes · suffix class-specific suffixes · updated
Quick answer
- Big picture: type 2 diabetes drugs come in subclasses that each work differently. Metformin (a biguanide) is first-line, sulfonylureas push the pancreas to release insulin, DPP-4 inhibitors (-gliptin) and GLP-1 agonists (semaglutide, dulaglutide) act on the incretin system, and SGLT2 inhibitors (-gliflozin) dump glucose into the urine.
- High-yield suffixes: the -gliptin ending signals a DPP-4 inhibitor (sitagliptin is Januvia) and the -gliflozin ending signals an SGLT2 inhibitor (empagliflozin is Jardiance). Most GLP-1 agonists end in -glutide (semaglutide is Ozempic for type 2 diabetes and Wegovy for weight management).
- Safety cues: metformin carries a rare lactic acidosis risk and is held around iodinated contrast imaging in at-risk patients (reduced kidney function, liver disease, alcoholism, heart failure, or intra-arterial contrast), sulfonylureas cause hypoglycemia and weight gain, SGLT2 inhibitors cause urinary and genital yeast infections, and GLP-1 agonists cause nausea and weight loss.
What gets tested
- Matching brand to generic across subclasses (Glucophage is metformin, Januvia is sitagliptin, Jardiance is empagliflozin, Ozempic is semaglutide)
- Reading the -gliptin suffix as DPP-4 inhibitor, the -gliflozin suffix as SGLT2 inhibitor, and the -glutide suffix as GLP-1 agonist
- Knowing metformin is first-line, works in the liver, and is held around iodinated contrast imaging in patients with reduced kidney function or other lactic acidosis risk factors
- Recognizing that sulfonylureas (glipizide, glimepiride, glyburide) stimulate insulin release and can cause hypoglycemia and weight gain
- Identifying the signature side effects of SGLT2 inhibitors (genital and urinary infections) and GLP-1 agonists (nausea, weight loss, often weekly injections)
- Telling Ozempic (type 2 diabetes) apart from Wegovy (chronic weight management), since both are semaglutide but are different products that are never swapped for each other
What is not tested
You do not need to memorize A1C or blood glucose target numbers, the prescriber's dose titration algorithm, or the detailed biochemistry of the incretin pathway. You do still need the practical product facts, because the exam covers strengths and doses, dosage forms, routes of administration, special handling and administration instructions, and duration of therapy: know that metformin is an oral tablet that comes in immediate release and extended release forms, that Ozempic and Trulicity are weekly subcutaneous pens, that Victoza is a daily pen, and that semaglutide also comes as an oral tablet. Insulin is its own separate class (rapid, short, intermediate, and long acting products) and is studied on its own rather than as an oral antidiabetic. What the exam does not ask you to do is choose or adjust a patient's therapy.
Why antidiabetic drugs matter
Diabetes drugs are dispensed constantly, and metformin is one of the most prescribed medications in the United States. GLP-1 agonists such as semaglutide (Ozempic for type 2 diabetes, Wegovy for chronic weight management) and SGLT2 inhibitors are among the fastest-growing prescriptions, so technicians see them daily. Because the class spans several subclasses with distinct suffixes and safety points, it is high-yield for the Medications domain.
Antidiabetic Drugs at a glance
| Generic | Brand | Primary indication |
|---|---|---|
| metformin | Glucophage (Glumetza, Fortamet) | type 2 diabetes (biguanide, first-line) |
| glipizide | Glucotrol | type 2 diabetes (sulfonylurea) |
| glimepiride | Amaryl | type 2 diabetes (sulfonylurea) |
| glyburide | DiaBeta (Glynase) | type 2 diabetes (sulfonylurea) |
| sitagliptin | Januvia | type 2 diabetes (DPP-4 inhibitor) |
| linagliptin | Tradjenta | type 2 diabetes (DPP-4 inhibitor) |
| saxagliptin | Onglyza | type 2 diabetes (DPP-4 inhibitor) |
| empagliflozin | Jardiance | type 2 diabetes, heart failure, and chronic kidney disease (SGLT2 inhibitor) |
| dapagliflozin | Farxiga | type 2 diabetes, heart failure, and chronic kidney disease (SGLT2 inhibitor) |
| canagliflozin | Invokana | type 2 diabetes and diabetic kidney disease (SGLT2 inhibitor) |
| semaglutide | Ozempic; Wegovy; Rybelsus (oral tablet) | type 2 diabetes as Ozempic and Rybelsus (GLP-1 agonist); the Wegovy brand of semaglutide is approved for chronic weight management, not for blood glucose control |
| dulaglutide | Trulicity | type 2 diabetes (GLP-1 agonist, weekly injection) |
| liraglutide | Victoza | type 2 diabetes (GLP-1 agonist, daily injection) |
| pioglitazone | Actos | type 2 diabetes (thiazolidinedione) |
| repaglinide | Prandin | type 2 diabetes (meglitinide) |
Mechanism of action
Antidiabetic drugs lower blood glucose through several distinct mechanisms, one per subclass. Metformin, a biguanide, decreases glucose production by the liver, slows intestinal glucose absorption, and improves the body's sensitivity to insulin, which is why it is first-line and does not by itself cause hypoglycemia. Sulfonylureas (glipizide, glimepiride, glyburide) and the short-acting meglitinides (repaglinide) stimulate the pancreas to release more insulin. DPP-4 inhibitors, the gliptins (sitagliptin, linagliptin, saxagliptin), block the enzyme that breaks down incretin hormones, which raises insulin and lowers glucagon after meals. GLP-1 receptor agonists (semaglutide, dulaglutide, liraglutide) are incretin mimetics, usually given by injection but also available as an oral semaglutide tablet, that boost glucose-dependent insulin release, slow stomach emptying, and reduce appetite, so they often cause weight loss. SGLT2 inhibitors, the gliflozins (empagliflozin, dapagliflozin, canagliflozin), block glucose reabsorption in the kidney so extra glucose leaves in the urine. Pioglitazone, a thiazolidinedione, improves insulin sensitivity in fat and muscle. Insulin itself is a separate injectable class used when these agents are not enough.
Common and important side effects
- Metformin: gastrointestinal upset (nausea, diarrhea, metallic taste), vitamin B12 deficiency with long-term use, and rare but serious lactic acidosis, especially with kidney impairment
- Sulfonylureas and meglitinides: hypoglycemia (low blood sugar) and weight gain because they raise insulin directly
- DPP-4 inhibitors (-gliptin): generally well tolerated, with headache, upper respiratory symptoms, and rare severe joint pain or pancreatitis; saxagliptin (Onglyza) and alogliptin also carry a warning about hospitalization for heart failure
- SGLT2 inhibitors (-gliflozin): genital yeast infections, urinary tract infections, increased urination, dehydration, and rare euglycemic ketoacidosis
- GLP-1 agonists (-glutide): nausea, vomiting, diarrhea, decreased appetite and weight loss, with a boxed warning about thyroid C-cell tumors and a risk of pancreatitis
- Thiazolidinedione (pioglitazone): fluid retention, edema, weight gain, decreased bone density, and a bladder cancer signal, with a boxed warning for congestive heart failure (starting it is contraindicated in NYHA class III or IV heart failure)
Key interactions
- Metformin is stopped at the time of or before iodinated contrast imaging in patients with an eGFR of 30 to 60, a history of liver disease, alcoholism, or heart failure, or who will receive intra-arterial contrast, because reduced kidney function can raise the risk of lactic acidosis. Kidney function is rechecked 48 hours later before metformin is restarted.
- Alcohol increases the lactic acidosis risk with metformin and can worsen hypoglycemia with sulfonylureas
- Combining a sulfonylurea, meglitinide, or insulin with another glucose-lowering drug increases the chance of hypoglycemia
- Beta blockers can mask the warning signs of hypoglycemia (such as a fast heartbeat), which matters most with sulfonylureas and insulin
- Diuretics and other drugs that raise blood sugar can reduce the effect of antidiabetic agents
- Repaglinide (Prandin) must not be taken with gemfibrozil, which raises repaglinide levels about eightfold and can cause severe hypoglycemia
Patient counseling notes
- Know the signs of low blood sugar (shakiness, sweating, dizziness, hunger, fast heartbeat) and keep a fast sugar source handy, especially with sulfonylureas and insulin
- Take metformin with food to reduce stomach upset, and report muscle pain, trouble breathing, or unusual tiredness that could signal lactic acidosis
- With SGLT2 inhibitors, stay hydrated and watch for genital itching or burning with urination, which can signal a yeast or urinary infection
- GLP-1 injections such as Ozempic and Trulicity are often given once weekly under the skin, and nausea usually eases over time as the dose is increased slowly
- Ozempic and Wegovy are both semaglutide, but they are different products with different pens, strengths, and approved uses, so they are never substituted for each other at the counter
- Do not stop a diabetes medication without talking to the prescriber, and keep taking it even when feeling well
Practice questions
Then test the whole class in context with the drug class identification quiz and the brand and generic quiz.
1. A prescription is written for Januvia. Which generic drug should the technician expect to dispense?
- A. Sitagliptin ✓
- B. Empagliflozin
- C. Glipizide
- D. Semaglutide
Answer: A. Januvia is the brand name for sitagliptin, a DPP-4 inhibitor. The -gliptin suffix identifies the DPP-4 class. The distractors are an SGLT2 inhibitor, a sulfonylurea, and a GLP-1 agonist.
2. The suffix -gliflozin, as in empagliflozin, identifies which class of antidiabetic drug?
- A. Sulfonylureas
- B. DPP-4 inhibitors
- C. SGLT2 inhibitors ✓
- D. Biguanides
Answer: C. The -gliflozin ending signals an SGLT2 inhibitor such as empagliflozin (Jardiance) or dapagliflozin (Farxiga). These drugs lower glucose by increasing how much glucose leaves the body in the urine.
3. Metformin is usually held around the time of a procedure using iodinated contrast dye in at-risk patients. Why?
- A. It stains the contrast image
- B. Reduced kidney function can raise the risk of lactic acidosis ✓
- C. It causes severe hypoglycemia during imaging
- D. It reacts with the dye to form crystals
Answer: B. Contrast dye can transiently reduce kidney function, and impaired kidneys plus metformin raise the risk of the rare but serious complication lactic acidosis. The labeling directs holding metformin around imaging for patients with an eGFR of 30 to 60, a history of liver disease, alcoholism, or heart failure, or who receive intra-arterial contrast, with kidney function rechecked 48 hours later before restarting.
4. A patient starting an SGLT2 inhibitor should be counseled to watch for which characteristic side effect?
- A. Persistent dry cough
- B. Genital yeast and urinary tract infections ✓
- C. Muscle pain and dark urine
- D. Ringing in the ears
Answer: B. Because SGLT2 inhibitors push extra glucose into the urine, that sugar-rich environment promotes genital yeast infections and urinary tract infections, which are the signature adverse effects of the class.
5. Which antidiabetic class is given as a subcutaneous injection (often once weekly), commonly causes nausea, and frequently leads to weight loss?
- A. Sulfonylureas
- B. GLP-1 receptor agonists ✓
- C. Biguanides
- D. DPP-4 inhibitors
Answer: B. GLP-1 receptor agonists such as semaglutide (Ozempic) and dulaglutide (Trulicity) are incretin mimetics given under the skin. They slow stomach emptying and reduce appetite, so nausea and weight loss are common. Semaglutide also comes as an oral tablet, but the class is most often injected.
Cheat sheet
- Metformin (Glucophage): biguanide, first-line, works in the liver, GI upset, low vitamin B12 with long-term use, rare lactic acidosis, hold around contrast dye in at-risk patients
- Sulfonylureas (glipizide, glimepiride, glyburide): stimulate insulin release, cause hypoglycemia and weight gain
- DPP-4 inhibitors, suffix -gliptin (sitagliptin is Januvia): incretin enzyme blockers, well tolerated
- SGLT2 inhibitors, suffix -gliflozin (empagliflozin is Jardiance, dapagliflozin is Farxiga): glucose out in urine, yeast and urinary infections, also used in heart failure and chronic kidney disease
- GLP-1 agonists, mostly -glutide (semaglutide is Ozempic for type 2 diabetes and Wegovy for weight management, dulaglutide is Trulicity): usually injections, oral semaglutide tablets also exist, nausea, weight loss
- Pioglitazone (Actos): thiazolidinedione, edema and weight gain, boxed warning for congestive heart failure, do not start in NYHA class III or IV heart failure
- Note: insulin is a separate injectable class studied on its own
Related drug-class guides
Official sources
- StatPearls: Oral Antidiabetic Medications (NBK482386)
- StatPearls: Metformin (NBK518983)
- StatPearls: Sulfonylureas (NBK513225)
- StatPearls: Dipeptidyl Peptidase IV (DPP-4) Inhibitors (NBK542331)
- StatPearls: Sodium-Glucose Transport 2 (SGLT2) Inhibitors (NBK576405)
- StatPearls: Glucagon-Like Peptide-1 Receptor Agonists (NBK551568)
- MedlinePlus: Type 2 diabetes, oral medicines
- MedlinePlus: GLP-1 agonists
- MedlinePlus: Semaglutide Injection (Ozempic, Wegovy)
- FDA label: Glucophage (metformin hydrochloride)
- DailyMed: Ozempic (semaglutide) label
- DailyMed: Actos (pioglitazone) label
- DailyMed: Prandin (repaglinide) label
- ClinCalc DrugStats: Metformin (dispensing rank)
PTCB Quiz Prep is an independent study resource, not affiliated with the Pharmacy Technician Certification Board. This guide is for exam preparation, not medical advice. See our editorial standards. Part of the PTCB Medications domain.